"high" and "low" UHRF2 expressing groups. Cases among the "high" group were more likely to be associated with a greater proportion of nuclei that overexpressed the p53 gene product (Fisher exact test, P < .05). However, UHRF2 expression did not correlate with a high Ki67 defined proliferative index, high percent tumor infiltrating T cells, nuclear PAX-5 expression, germinal center subtype, or overall survival. Conclusions: We conclude that UHRF2 is universally expressed in all DLBCL cases in our study, and there is an association between high expression of UHRF2 and overexpression of the p53 protein. This association may implicate a role of UHRF2 in lymphomagenesis and/or tumor maintenance in the subset of DLBCL cases that express high levels of p53.
Inaccurate Hemoglobin S+C Estimates Prior to Emergent Red Blood Cell Exchange Procedures Lead to Overtransfusion
Jeffrey Papiernik, Ronald Jackups;Washington University, St Louis, MO Background: As a therapeutic treatment for sickle cell disease, red blood cell (RBC) exchange rapidly removes unwanted hemoglobin (Hgb) S and C and replaces it with donated RBC units containing mainly Hgb A. Determining how much blood to deliver to reach the targeted goal, however, requires laboratory testing for the current measure of abnormal hemoglobin. If results are unknown prior to the start of the procedure, especially in emergent situations, the level must be estimated. We investigated to what degree these estimates led to inappropriate overtransfusion or undertransfusion in our patient population. Methods: This was a retrospective, observational study from 2011 to 2016 of patients who had completed one or more RBC exchange procedures in the inpatient setting at a large academic medical center. The following information was obtained: history of disease, number of procedures received, emergent status of procedures, number of RBC units per procedure, goal Hgb S+C percentage, goal fraction of cells remaining (FCR), and Hgb S+C percentages measured pre-and postprocedure. Procedures that lacked any of the latter three pieces of information were not included in the analysis. Estimated preprocedural Hgb S+C percentage was calculated by dividing the Hgb S+C goal by the FCR. Overtransfusion and undertransfusion were determined by comparing the original FCR to an FCR calculated using the actual preprocedural and goal Hgb S+C percentages. Results: During the study period, 378 RBC exchange procedures were assessed. Three primary groups of procedures were evaluated: emergent procedures with unknown preprocedural Hgb S+C percentage (E-U), nonemergent procedures with unknown preprocedural Hgb S+C percentage (NE-U), and procedures with known preprocedural Hgb S+C percentage (Kn). The percent difference between the estimated and actual preprocedural Hgb S+C levels was calculated for each procedure. The median difference (and range) for the E-U, NE-U, and Kn groups was 26.6% (-9.8%-270.4%), 1.6% (-33.5%-311.0%), and 1.3% (-19.5%-118.0%), respectively. The E-U group was significantly different from the other two groups (P < .0001), but the NE-U group was not different from the Kn group (P = .16). Undertransfusion occurred in 14% of procedures by a total of 38 RBC units, and overtransfusion in 39% of procedures by a total of 167 RBC units. Approximately 1/2 of the excess 167 units came from emergent procedures, despite comprising less than 20% of the total procedures. Conclusions: More than half of RBC exchange procedures (53%) resulted in the patient receiving an incorrect number of RBC units, mostly overtransfusion attributable to emergent procedures in which the lab results were still pending by the time the procedures began. These results suggest that a rapid turnaround time method should be available to measure abnormal hemoglobin levels prior to the start of RBC exchange. immunoassays before and after treatment of samples with heterophile blocking reagent (HBR) nonmurine solution (Beckman assay) and heterophile blocking tubes (HBT) (Roche assay; Scantibodies Laboratory). The absolute difference and the percent difference between untreated and treated results were calculated. Serial dilutions were also performed (primary method) and percent recovery calculated. Results: From the 112 physician requests, five cases of HA interference were identified. The HA frequency was 6.7% (n = 3) for the Beckman assay and 3.0% (n = 2) for the Roche assay. The range of hCG concentrations on all the evaluated samples was 0.1-2,797.0 IU/L (mean 71.1 IU/L; median: 10.2 IU/L). The presence of HA was detected using HBR/HBT reagents in three cases with a percent difference from the untreated sample of -80%, -51%, and -64% from the initial value of 13, 5.5, and 9 IU/L, respectively. The two cases not detected by HBR/ HBT reagents were detected due to discrepant results with the secondary method (50.44 vs 1.74 IU/L and 56.6 vs <1.0 IU/L) and nonlinear serial dilution (recovery outside 80%-120%). HA-negative cases showed an absolute difference of ±0.9 IU/L at <10 IU/L and percent difference ≤+/-20% from the untreated at concentrations >10 IU/L for the Beckman assay; and an absolute difference of ±1.2 U/L at <10 IU/L and a ≤+/-10% difference from the untreated at concentrations >10 IU/L for the Roche assay. Conclusions: Frequency of HA interference was similar between the Beckman and the Roche assays (6.7 vs 3.0%, P = .357). The HBR/HBT blocking reagents failed to detect 40% of HA interference cases and should not be solely used for these investigations. Multiple strategies including the use of serial dilutions and measurement using an alternative platform are critical to identify the presence of HA. Background: Folate is a water-soluble vitamin essential for cell growth and division. RBC folate determination is obtained by measuring the folate concentration in a whole blood (WB) hemolysate solution and dividing it by the patient's hematocrit (Hct; %). RBC folate presents a logistical challenge in the context of send-out testing; frozen storage is ideal for WB specimens prior to folate testing, although freezing lyses RBCs. A corresponding nonfrozen WB specimen or a supplied Hct (from the specimen prior to freezing) is therefore required. The following experiments were performed to determine whether hemoglobin (Hb) measurement from the hemolysate used for corresponding folate testing can accurately estimate Hct and therefore be used in calculating RBC folate. Methods: Fifty-four residual, clinical WB specimens previously tested for RBC folate on Beckman UniCel DXI 800 immunoanalyzers were obtained from -20°C storage and deidentified according to a protocol approved by the internal review board. Client laboratory-supplied Hct (cHct), which spanned low to high values, was recorded for each specimen. Two hemolysates were generated from WB samples using vendor-specific ascorbic acid solutions and tested for folate on their corresponding instruments (ie, UniCel DXI 800 and Roche Cobas e602). Hb measurement on both hemolysates was then performed on a Roche Cobas c501 instrument using a Pointe Scientific cyanmethemoglobin assay. Hemolysate Hb results were compared to the cHct values using Pearson correlation, and a linear regression model was used to estimate Hct (eHct). RBC folate was compared using hemolysate folate (from Beckman and Roche platforms) with both cHct and eHct values. Results: Specimens from 26 men (age, mean ± SD: 54.0 ± 24.3 yr) and 28 women (age, mean ± SD: 56.6 ± 18.9 yr) were included in the study. The cHct of specimens used in this study ranged from 16.2% to 58.6% (mean ± SD: 34.8 ± 8.2%). Using cHct values, RBC folate results from Beckman and Roche immunoassays ranged from 205 to 1,684 ng/mL and 548 to 1,896 ng/mL, respectively. The Pearson correlation between the RBC folate values obtained on the two platforms using cHct was approximately 93%. There was a substantial correlation between cHct and eHct, using hemolysates generated with Beckman (Pearson correlation at 95%) or Roche (Pearson correlation at 91%) protocol dilutions. The RBC folate values calculated based on eHct showed strong correlation with values calculated using cHct on both platforms: Pearson correlation values of 98% (Beckman) and 92% (Roche). Conclusion: Our results demonstrate that Hct can be accurately estimated from Hb measured in the same hemolysate used for folate testing. This process may eliminate the need for pretesting of Hct prior to frozen transport and enable greater automation of RBC folate testing by laboratories.
